Amarin Corp PLC (AMRN): Total Liabilities
$211.49M
As of 2025-12-31
$180.75M
As of 2026-06-30
-10.1%
3-year compound annual growth
-9.0%
5-year compound annual growth
-3.5%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $211.49M | +6.2% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $199.17M | -28.8% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $279.59M | -3.9% | 2025-03-12, Balance as of period end |
| 2022-12-31 | $290.85M | -27.5% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $400.97M | +18.4% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $338.52M | +23.6% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $273.95M | +17.4% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $233.38M | +2.9% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $226.70M | +28.8% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $176.06M | -41.5% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $300.78M | +15.9% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $259.56M | -9.4% | 2016-02-25, Balance as of period end |
| 2013-12-31 | $286.33M | -9.1% | 2015-03-03, Balance as of period end |
| 2012-12-31 | $314.85M | +137.9% | 2014-02-27, Balance as of period end |
| 2011-12-31 | $132.34M | -44.3% | 2013-02-28, Balance as of period end |
| 2010-12-31 | $237.73M | n/a | 2012-02-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Amarin Corp PLC (AMRN) | 2025-12-31 | $211.49M | +6.2% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $161.76M | +37.5% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $86.39M | +33.0% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $85.96M | -29.1% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $343.95M | +27.5% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $34.89M | -21.3% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $397.87M | -7.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $65.98M | +55.1% |
Compare AMRN, VNDA, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗